title: [Reduced intensity allogenic hematopoietic stem cell transplantation in children].
abstract: Better understanding of the antitumor effect of allogeneic transplant and the need to reduce the toxicity of the procedure, particularly in elderly patients have spurred the development of reduced-intensity conditioning regimens (RIC). These regimens allow fast engraftment with very low chemotherapy-induced toxicity. They are widely used in adults and there are numerous studies to demonstrate their feasibility and efficiency, but in pediatrics, the place of RIC remains to be determined. They can be proposed in two pediatric populations. First, solid tumors or hematological malignancies remaining unresponsive to the reference strategies according to best practices in pediatrics. Second, in children presenting malignancies for which allografting is the only recognized curative indication but is contraindicated with myeloablative conditioning regimens. More than 100 pediatrics cases have been reported in various pathologies, including blood diseases, acute leukemia, Hodgkin's lymphoma and solid tumors, and promising results published recently underline how RIC warrants further investigation in prospective comparative multicentric trials. The use of new post-graft treatment modalities is expected to pave the way to the development of RIC in pediatric patients.
authors.affiliation: CHU de Clermont-Ferrand, Centre régional de cancérologie et de thérapie cellulaire pédiatrique, Inserm CIC 501, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France. cpaillard@chu-clermontferrand.fr
authors.forename: Catherine
authors.initials: C
authors.lastname: Paillard
authors.forename: Patrick
authors.initials: P
authors.lastname: Lutz
authors.forename: Gérard
authors.initials: G
authors.lastname: Michel
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
authors.forename: Jean-Hugues
authors.initials: JH
authors.lastname: Dalle
authors.forename: François
authors.initials: F
authors.lastname: Demeocq
authors.forename: Justyna
authors.initials: J
authors.lastname: Kanold
mesh_terms: D002648:Child; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods